Mon, Jul 28, 2014, 11:58 AM EDT - U.S. Markets close in 4 hrs 2 mins

Recent

% | $
Click the to save as a favorite.

Omeros Corporation (OMER) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • bioklhk bioklhk Nov 23, 2009 3:19 PM Flag

    Lawsuit filed by ex CFO

    <<Obviously a disgruntled employee who was fired with cause>>

    The cause was obviously Mr. Klein was not a "yes man" to CEO Gregory A. Demopulos.

    <<Gregory A. Demopulos... in an interim capacity, as our chief financial officer and treasurer since January 2009.>>

    http://www.sec.gov/Archives/edgar/data/1285819/000095012309049121/f35568b4e424b4.htm#111


    What is Demopulos' training in accounting and corporate finance that makes him qualified to serve as the chief financial officer and treasurer of a publicly traded company even only in an interim capacity?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Why wouldn't they do as is usually the case, have a board member, say the audit committe chairman fill an interim role, while the search runs its course. Maybe the board member had no interest in signing the SEC docs and certifications .. CEO Gregg did it in all fidudciary capacities.

      Now I may be magic's eunuch (pretty good squidster) but I know it ain't right to have the chicken coop guarded by off leash canine inside cronies while the CFO role is unoccupied. Anyone know the audit committee chair and the level of involve ment in financial oversight ?

      • 1 Reply to precisioncastrated
      • How about the controller? According to their website, David Toll has been controller since Nov 2000 and is now Director of Finance. Why not name a veteran controller the interim CFO until someone is hired to fill the CFO slot? Seems investors (and SEC) would want to know that there is some bench strength in the finance/control side of the organization

    • http://industry.bnet.com/pharma/10005233/scandal-provides-another-reason-omeros-might-not-be-the-biotech-ipo-bellwether/

      Scandal Provides Another Reason Omeros Might Not Be the Biotech IPO Bellwether

      By Trista Morrison | Nov 10, 2009

      As more biotech companies queue up to try their hand at an initial public offering, there’s scandal-driven evidence that Omeros Corp.’s recent IPO flop may not be indicative of investor appetite for the biotech sector.

      Omeros has so far been the only “true biotech” (i.e. money-losing, developmental-stage biotech) to go public in the current IPO window. The company priced at the low end of its target range and has so far been among the worst performers of all U.S. IPOs this year, according to Renaissance Capital.

      But as BNET previously noted, Omeros might not be the ideal biotech to benchmark against. For starters, the company was a holdover from the last IPO window, which indicates persistence perhaps to the point of desperation. And while Omeros is in Phase III trials, its lead product is a generic combo drug for surgical applications (though heck, generic combos haven’t drawn disdain in the obesity sector).

      Now Luke Timmerman over at Xconomy reports that Omeros has been accused of “submitting false timekeeping records to the National Institutes of Health for grant work.” The company’s former chief financial officer, Richard Klein, says he was fired for blowing the whistle on the scandal. Omeros said it did not overbill the NIH.

      The Xconomy article also states that Klein accused Omeros of “making false statements” regarding the incident in its IPO prospectus, and it recounts Klein’s previous accusations regarding Omeros CEO Greg Demopulos‘ questionable tax practices:

      For example, in 2007, according to Klein’s complaint, Demopulos exercised stock options “and attempted to avoid reporting the taxable income or paying the taxes resulting from the option exercise as required by Federal tax law.” After Klein found this out, his complaint says, he required Demopulos to report the taxable income to the IRS.

      All of this could mean that Omeros’ poor IPO performance is tied to factors other than the company’s “biotech” status. One banker likened Omeros to Acusphere, a drug delivery firm that’s lackluster IPO at the beginning of the 2003 window did nothing to deter investor interest in subsequent biotech offerings.

      For the sake of all the other biotechs waiting in the wings to go public, let’s hope that’s the case.

 
OMER
13.57-0.41(-2.93%)11:58 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.